Santarpia M - Search Results

1

On the pharmacogenetics of non-small cell lung cancer treatment.

Santarpia M, Rolfo C, Peters GJ, Leon LG, Giovannetti E. Santarpia M, et al. Expert Opin Drug Metab Toxicol. 2016;12(3):307-17. doi: 10.1517/17425255.2016.1141894. Epub 2016 Feb 17. Expert Opin Drug Metab Toxicol. 2016. PMID: 26761638 Review.

2

Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going.

Rosell R, Cuello M, Cecere F, Santarpia M, Reguart N, Felip E, Taron M. Rosell R, et al. Among authors: santarpia m. Curr Opin Oncol. 2006 Mar;18(2):135-43. doi: 10.1097/01.cco.0000208786.91947.eb. Curr Opin Oncol. 2006. PMID: 16462182 Review.

3

From the bench to the bed: individualizing treatment in non-small-cell lung cancer.

Santarpia M, Altavilla G, Salazar F, Tarón M, Rosell R. Santarpia M, et al. Clin Transl Oncol. 2006 Feb;8(2):71-6. doi: 10.1007/s12094-006-0161-2. Clin Transl Oncol. 2006. PMID: 16632419 Review.

4

Predicting the outcome of chemotherapy for lung cancer.

Rosell R, Cecere F, Santarpia M, Reguart N, Taron M. Rosell R, et al. Among authors: santarpia m. Curr Opin Pharmacol. 2006 Aug;6(4):323-31. doi: 10.1016/j.coph.2006.01.011. Epub 2006 Jun 12. Curr Opin Pharmacol. 2006. PMID: 16765644 Review.

5

Emerging drugs for non-small-cell lung cancer.

Felip E, Santarpia M, Rosell R. Felip E, et al. Among authors: santarpia m. Expert Opin Emerg Drugs. 2007 Sep;12(3):449-60. doi: 10.1517/14728214.12.3.449. Expert Opin Emerg Drugs. 2007. PMID: 17874972 Review.

6

Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases.

Altavilla G, Arrigo C, Santarpia MC, Galletti G, Picone G, Marabello G, Tomasello C, Pitini VV. Altavilla G, et al. J Neurooncol. 2008 Oct;90(1):31-3. doi: 10.1007/s11060-008-9623-4. Epub 2008 Jun 20. J Neurooncol. 2008. PMID: 18566747

7

Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive.

Santarpia M, Altavilla G, Salazar MF, Magri I, Pettineo G, Benecchi S, Rosell R. Santarpia M, et al. Expert Rev Respir Med. 2011 Jun;5(3):413-24. doi: 10.1586/ers.11.27. Expert Rev Respir Med. 2011. PMID: 21702662 Review.

8

Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients.

Santarpia M, De Pas TM, Altavilla G, Spaggiari L, Rosell R. Santarpia M, et al. Future Oncol. 2013 Mar;9(3):327-45. doi: 10.2217/fon.13.6. Future Oncol. 2013. PMID: 23469969

9

Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options.

Lazzari C, Spitaleri G, Catania C, Barberis M, Noberasco C, Santarpia M, Delmonte A, Toffalorio F, Conforti F, De Pas TM. Lazzari C, et al. Among authors: santarpia m. Crit Rev Oncol Hematol. 2014 Mar;89(3):358-65. doi: 10.1016/j.critrevonc.2013.09.003. Epub 2013 Sep 26. Crit Rev Oncol Hematol. 2014. PMID: 24156959 Review.

10

Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer.

Santarpia M, Altavilla G, Rosell R. Santarpia M, et al. Expert Rev Respir Med. 2015 Jun;9(3):255-68. doi: 10.1586/17476348.2015.1009040. Epub 2015 Feb 5. Expert Rev Respir Med. 2015. PMID: 25652176

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

126 results

Search Page